Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2NET 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 250Carcinoma, Renal Cell 89Urinary Bladder Neoplasms 67Breast Neoplasms 41Carcinoma, Transitional Cell 37Colorectal Neoplasms 33Ovarian Neoplasms 32Melanoma 31Carcinoma, Non-Small-Cell Lung 31Kidney Neoplasms 30Neoplasms 28Neoplasm Metastasis 26Sarcoma 25Uterine Cervical Neoplasms 20Lung Neoplasms 20Endometrial Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 19Wilms Tumor 17Adenocarcinoma 17Stomach Neoplasms 16Pancreatic Neoplasms 16Carcinoma, Hepatocellular 16Triple Negative Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Metastatic Castration-resistant Prostate Cancer 13Esophageal Neoplasms 13Rhabdomyosarcoma 12Osteosarcoma 12Neuroblastoma 12Head and Neck Neoplasms 12

Interventions

pembrolizumab 1PT-100 dipeptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Genitourinary × 30 days × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡